Ignite Creation Date:
2025-12-24 @ 6:59 PM
Ignite Modification Date:
2025-12-29 @ 9:49 PM
Study NCT ID:
NCT01359657
Status:
COMPLETED
Last Update Posted:
2016-03-16
First Post:
2011-05-11
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Anti-CXCR4 (BMS-936564) Alone and in Combination With Lenalidomide/Dexamethasone or Bortezomib/Dexamethasone in Relapsed/Refractory Multiple Myeloma
Sponsor:
Bristol-Myers Squibb
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2011-09
Start Date Type:
None
Primary Completion Date:
2016-03
Primary Completion Date Type:
ACTUAL
Completion Date:
2016-03
Completion Date Type:
ACTUAL
First Submit Date:
2011-05-11
First Submit QC Date:
None
Study First Post Date:
2011-05-25
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2016-03-15
Last Update Post Date:
2016-03-16
Last Update Post Date Type:
ESTIMATED